Aardvark Therapeutics, Inc. 8-K

What Happened

• On January 12, 2026, Aardvark Therapeutics, Inc. announced it updated its corporate presentation for use in investor, analyst and other meetings and will post the presentation on the company website. The presentation is filed as Exhibit 99.1 to the Current Report on Form 8-K. The filing was signed by Chief Executive Officer Tien-Li Lee, M.D.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Item 8.01 Other Events).
• Exhibit filed: 99.1 — Corporate Presentation, dated January 2026.
• The presentation will be posted to Aardvark’s website and is incorporated by reference into the 8-K.
• Report signed by CEO Tien-Li Lee, M.D.

Why It Matters

• The filing signals that Aardvark has refreshed its investor materials; investors can review the newly filed presentation for the company’s latest public messaging, updates on strategy, programs, timelines or other corporate information.
• This 8-K does not report financial results, executive changes, or a transaction — it is limited to making updated corporate presentation materials available to the public.